PlaqueTec Innovates Precision Medicine for Coronary Artery Disease
PlaqueTec, a Cambridge, UK-based company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), has recently secured £6.4M in funding. The round was led by Lord Moynihan of Chelsea alongside the Future Fund, with support from existing investors. This financial injection will be pivotal in supporting PlaqueTec's ongoing Biopattern trial, aimed at improving the understanding of CAD pathobiology and its variations between individuals. Additionally, the funds will also be used to further develop Biocarta®, the company's innovative biomarker discovery tool.
Under the leadership of Chairman Martin Stapleton, PlaqueTec is at the forefront of identifying endotype-specific biomarkers to advance precision medicine for CAD.
In a world where CAD is a leading global cause of death due to atherosclerotic plaque build-up that restricts blood flow to the heart, the company's proprietary technology and data analysis platform offer hope. By defining endotypes and uncovering potential biomarkers related to coronary vascular function and plaque progression, PlaqueTec is revolutionizing the understanding and treatment of this deadly disease.
At the heart of PlaqueTec's groundbreaking work is BIOCARTA, a bioinformatics discovery platform that analyzes patient data and categorizes individuals with CAD into distinct endotypes. By correlating in vivo biomarkers, plaque imaging, genomic analysis, blood biochemistry, and clinical phenotypes, BIOCARTA provides a comprehensive understanding of the disease. This unique approach allows PlaqueTec to identify biomarkers that accurately assess patients and guide targeted therapeutic interventions, ultimately transforming the landscape of patient care in the realm of CAD.
They've invested in PlaqueTec
Get to know these Biotech investors
Click here for a full list of 6,908+ startup investors in the UK